Bermekimab Explained

Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.

Bermekimab is being developed by XBiotech Inc.[3]

Notes and References

  1. http://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fbermekimab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab
  2. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R . 6 . MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study . The Lancet. Oncology . 15 . 6 . 656–66 . May 2014 . 24746841 . 10.1016/S1470-2045(14)70155-X .
  3. Web site: Xilonix True Human monoclonal antibody by Xbiotech oncology . www.xbiotech.com . XBiotech . 3 March 2017 . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bermekimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.